Table 1.
Characteristics of the 160 gastric cancer patients
| Characteristics | Total (n = 160) | Death (n = 11) | Survival (n = 149) | P |
|---|---|---|---|---|
| Mean age (range), y | 64.6 (30‐89) | 70.7 (43‐87) | 64.1 (30‐89) | .1584 |
| Sex, n (%) | ||||
| Female | 70 (43.8%) | 7 (63.6%) | 63 (42.3%) | .2134 |
| Male | 90 (56.3%) | 4 (36.4%) | 86 (57.7%) | |
| Mean BMI (range), kg/m2 | 22.5 (15.9‐32.8) | 22.3 (15.9‐31.6) | 22.6 (16.7‐32.8) | .8400 |
| Past history of cancer, yes | 28 (17.5%) | 1 (9.09%) | 27 (18.1%) | .6907 |
| Family history of gastric cancer, yes | 47 (29.4%) | 3 (27.3%) | 44 (29.5%) | .7030 |
| Smoking | ||||
| None | 105 (65.6%) | 7 (63.6%) | 98 (65.8%) | .8900 |
| Brinkman Index <400 | 21 (13.1%) | 2 (18.2%) | 19 (12.8%) | |
| Brinkman Index ≥400 | 29 (18.1%) | 2 (18.2%) | 27 (18.1%) | |
| Alcohol | ||||
| None | 63 (39.4%) | 6 (54.5%) | 58 (38.9%) | .6259 |
| <20 g/d | 46 (28.8%) | 2 (18.2%) | 44 (29.5%) | |
| ≥20 g/d | 45 (28.1%) | 3 (27.3%) | 42 (28.2%) | |
| Endoscopy within 2 y, yes | 59 (36.9%) | 0 | 59(39.6%) | .00738a |
| Helicobacter pylori status | ||||
| Persistent infection | 89 (55.6%) | 10 (90.9%) | 79 (53.0%) | .0400a |
| Successful eradication therapy | 53 (33.1%) | 0 | 53 (35.5%) | |
| Eradicated spontaneously | 12 (7.50%) | 1 (9.09%) | 11 (7.38%) | |
| Uninfected | 6 (3.75%) | 0 | 6 (4.03%) | |
| Atrophic gastritis | ||||
| None | 6 (3.75%) | 0 | 6 (4.03%) | .5967 |
| C‐1 | 0 | 0 | 0 | |
| C‐2 | 16 (1.00%) | 0 | 16 (10.7%) | |
| C‐3 | 9 (5.63%) | 0 | 9 (6.04%) | |
| O‐1 | 18 (11.9%) | 0 | 18 (12.1%) | |
| O‐2 | 27 (16.9%) | 3 (27.9%) | 24 (16.1%) | |
| O‐3 | 84 (69.3%) | 8 (72.7%) | 76 (51.0%) | |
| Stage, n (%) | ||||
| I | 135 (84.4%) | 3 (27.3%) | 132 (88.6%) | <.0001a |
| II | 11 (6.88%) | 0 | 11 (7.38%) | |
| III | 7 (4.38%) | 2 (18.2%) | 5 (3.36%) | |
| IV | 7 (4.38%) | 6 (54.5%) | 1 (0.67%) | |
| Location | ||||
| Upper third | 30 (18.8%) | 6 (54.5%) | 24 (16.1%) | .0034a |
| Middle third | 71 (44.4%) | 1 (9.09%) | 70 (47.0%) | |
| Lower third | 59 (36.9%) | 4 (36.4%) | 55 (36.9%) | |
| Mean size (range), mm | 28.9 (1.0‐160) | 68.1 (10‐120) | 26.1 (1.0‐160) | .0061a |
| Pathology | ||||
| Intestinal type | 114 (71.3%) | 3 (27.9%) | 111 (74.5%) | .0022a |
| Diffuse type | 46 (28.8%) | 8 (72.7%) | 38 (25.5%) | |
| Treatment for gastric cancer | ||||
| Endoscopy | 88 (55.0%) | 2 (18.2%) | 86 (57.7%) | <.0001a |
| Surgery | 61 (38.1%) | 1 (9.09%) | 60 (40.3%) | |
| Chemotherapy | 5 (3.13%) | 4 (36.4%) | 1 (0.67%) | |
| Best supportive care | 2 (1.25%) | 2 (18.2%) | 0 | |
| Observation | 4 (2.50%) | 2 (18.2%) | 2 (1.34%) | |
| Observation period (range), y | 3.47 (0.08‐11.7) | 1.55 (0.15‐3.69) | 3.69 (0.08‐11.7) | <.0001a |
BMI, body mass index.
a
Statistically significant.